AFB was granted the FDA approval for the management of patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) with their tumors possess epidermal growth factor receptor (EGFR) exon 21 (L858R) substitution mutations or exon 19 deletions [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.